Evaluation of Efficacy and Safety of Rituximab in Patients With Progressive Interstitial Lung Disease (ILD) With Inflammatory Component: a Multicentre Double-blind Placebo-controlled Randomized Trial
Clinical trial NCT05596786 · UNKNOWN
Trial details
- NCT number
- NCT05596786
- Sponsor
- University Hospital, Tours
- Status
- UNKNOWN
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2023-01-16
- Primary completion
- 2026-07-16
- Enrollment
- 126
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.